InMed Pharmaceuticals (INM) Interest & Investment Income (2019 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Interest & Investment Income of $47770.0 for Q1 2026, up 188.38% year-over-year from $16565.0 in Q1 2025, and down 35.77% quarter-over-quarter from $74379.0 in Q4 2025.
InMed Pharmaceuticals (INM) Interest & Investment Income (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals' Interest & Investment Income history runs 8 years deep, the most recent figure standing at $47770.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 188.38% year-over-year to $47770.0; the TTM figure through Mar 2026 stood at $267601.0 (up 28.76% YoY), while the FY2025 annual figure was $155882.0, down 70.47% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $47770.0, down from $74379.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $166760.0 in Q4 2023, with the low at $16565.0 in Q1 2025.
- The 5-year median for Interest & Investment Income is $74379.0 (2025), against an average of $85694.2.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income jumped 1310.0% in 2022, then plunged 86.36% in 2025.
- InMed Pharmaceuticals' Interest & Investment Income stood at $115797.0 in 2022, then soared by 44.01% to $166760.0 in 2023, then plunged by 81.69% to $30536.0 in 2024, then jumped by 143.58% to $74379.0 in 2025, then plunged by 35.77% to $47770.0 in 2026.
- Business Quant data shows INM's Interest & Investment Income at $47770.0 in Q1 2026, $74379.0 in Q4 2025, and $93765.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.52 Mn | 1.28 Mn | - | 47,770.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47,770.00 |
| Dec 31, 2025 | 74,379.00 |
| Sep 30, 2025 | 93,765.00 |
| Jun 30, 2025 | 51,687.00 |
| Mar 31, 2025 | 16,565.00 |
| Dec 31, 2024 | 30,536.00 |
| Sep 30, 2024 | 57,094.00 |
| Jun 30, 2024 | 103,640.00 |
| Mar 31, 2024 | 121,458.00 |
| Dec 31, 2023 | 166,760.00 |
| Sep 30, 2023 | 136,043.00 |
| Jun 30, 2023 | 148,559.00 |
| Mar 31, 2023 | 155,497.00 |
| Dec 31, 2022 | 115,797.00 |
| Sep 30, 2022 | 72,587.00 |
| Jun 30, 2022 | 33,701.00 |
| Mar 31, 2022 | 30,964.00 |
| Dec 31, 2021 | 26,277.00 |
| Sep 30, 2021 | 5,148.00 |
| Jun 30, 2021 | 4,825.00 |